Literature DB >> 26378243

Targeting the glucocorticoid receptor in breast and prostate cancers.

Jacob Kach1, Suzanne D Conzen2, Russell Z Szmulewitz3.   

Abstract

Steroid receptors for androgens and estrogens have essential roles in prostate and breast cancers. Recently, glucocorticoid receptor (GR) activity has also been proposed as having an important role in these cancers. Underscoring the cooperative nature of nuclear receptor activity, data now suggest that GR function in prostate and breast cancers is dependent on the tumor's concomitant androgen or estrogen receptor activity.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26378243      PMCID： PMC4807967          DOI： 10.1126/scitranslmed.aac7531

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  33 in total

Review 1.  Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review.

Authors:  Marwan Fakih; Candace S Johnson; Donald L Trump
Journal:  Urology       Date:  2002-10       Impact factor: 2.649

Review 2.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

Authors:  Howard I Scher; Charles L Sawyers
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

3.  Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer.

Authors:  Deng Pan; Masha Kocherginsky; Suzanne D Conzen
Journal:  Cancer Res       Date:  2011-08-25       Impact factor: 12.701

4.  The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.

Authors:  Ning Xie; Helen Cheng; Dong Lin; Liangliang Liu; Ou Yang; Li Jia; Ladan Fazli; Martin E Gleave; Yuzhuo Wang; Paul Rennie; Xuesen Dong
Journal:  Int J Cancer       Date:  2014-08-27       Impact factor: 7.396

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

Review 6.  New targets for triple-negative breast cancer.

Authors:  Christina I Herold; Carey K Anders
Journal:  Oncology (Williston Park)       Date:  2013-09       Impact factor: 2.990

7.  A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes.

Authors: 
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

8.  Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma.

Authors:  J L Mohler; Y Chen; K Hamil; S H Hall; J A Cidlowski; E M Wilson; F S French; M Sar
Journal:  Clin Cancer Res       Date:  1996-05       Impact factor: 12.531

9.  Tumor clone dynamics in lethal prostate cancer.

Authors:  Suzanne Carreira; Alessandro Romanel; Jane Goodall; Emily Grist; Roberta Ferraldeschi; Susana Miranda; Davide Prandi; David Lorente; Jean-Sebastien Frenel; Carmel Pezaro; Aurelius Omlin; Daniel Nava Rodrigues; Penelope Flohr; Nina Tunariu; Johann S de Bono; Francesca Demichelis; Gerhardt Attard
Journal:  Sci Transl Med       Date:  2014-09-17       Impact factor: 17.956

10.  Coactivators enable glucocorticoid receptor recruitment to fine-tune estrogen receptor transcriptional responses.

Authors:  Michael J Bolt; Fabio Stossi; Justin Y Newberg; Arturo Orjalo; Hans E Johansson; Michael A Mancini
Journal:  Nucleic Acids Res       Date:  2013-02-26       Impact factor: 16.971
View more
  31 in total

1.  Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.

Authors:  Jacob Kach; Tiha M Long; Phillip Selman; Eva Y Tonsing-Carter; Maria A Bacalao; Ricardo R Lastra; Larischa de Wet; Shane Comiskey; Marc Gillard; Calvin VanOpstall; Diana C West; Wen-Ching Chan; Donald Vander Griend; Suzanne D Conzen; Russell Z Szmulewitz
Journal:  Mol Cancer Ther       Date:  2017-04-20       Impact factor: 6.261

2.  Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.

Authors:  Yoshitsugu Mitani; Sue-Hwa Lin; Kristen B Pytynia; Renata Ferrarotto; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2019-11-26       Impact factor: 12.531

3.  Association of lifestyle and demographic factors with estrogenic and glucocorticogenic activity in Mexican American women.

Authors:  L Fejerman; S S Sanchez; R Thomas; P Tachachartvanich; J Riby; S L Gomez; E M John; M T Smith
Journal:  Carcinogenesis       Date:  2016-07-13       Impact factor: 4.944

Review 4.  Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.

Authors:  Shawna B Matthews; Carol A Sartorius
Journal:  Horm Cancer       Date:  2016-10-28       Impact factor: 3.869

5.  Recent advances in understanding glucocorticoid receptor function in cancer.

Authors:  Suzanne D Conzen
Journal:  Clin Adv Hematol Oncol       Date:  2017-05

6.  Ras-ling with new therapeutic targets for metastasis.

Authors:  Joshua A Mason; Zachary T Schafer
Journal:  Small GTPases       Date:  2017-05-04

Review 7.  New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.

Authors:  Margaret M Centenera; Luke A Selth; Esmaeil Ebrahimie; Lisa M Butler; Wayne D Tilley
Journal:  Cold Spring Harb Perspect Med       Date:  2018-12-03       Impact factor: 6.915

8.  CUE domain-containing protein 2 promotes the Warburg effect and tumorigenesis.

Authors:  Xiuying Zhong; Shengya Tian; Xiang Zhang; Xinwei Diao; Fangting Dong; Jie Yang; Zhaoyong Li; Linchong Sun; Lin Wang; Xiaoping He; Gongwei Wu; Xin Hu; Lihua Wang; Libing Song; Huafeng Zhang; Xin Pan; Ailing Li; Ping Gao
Journal:  EMBO Rep       Date:  2017-03-21       Impact factor: 8.807

Review 9.  Family Matters: Collaboration and Conflict Among the Steroid Receptors Raises a Need for Group Therapy.

Authors:  Matthew J Sikora
Journal:  Endocrinology       Date:  2016-11-11       Impact factor: 4.736

10.  Glucocorticoid Receptor:MegaTrans Switching Mediates the Repression of an ERα-Regulated Transcriptional Program.

Authors:  Feng Yang; Qi Ma; Zhijie Liu; Wenbo Li; Yuliang Tan; Chunyu Jin; Wubin Ma; Yiren Hu; Jia Shen; Kenneth A Ohgi; Francesca Telese; Wen Liu; Michael G Rosenfeld
Journal:  Mol Cell       Date:  2017-05-04       Impact factor: 17.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.